OverviewSuggest Edit

Nanobiotix is a late stage clinical company pioneering nanomedicine for more than a decade. We intend to significantly change the outcomes for cancer patients following a different path than other Pharma or Biotech companies: a new way to treat patients thanks to nanophysics at the heart of the cell. Nanobiotix operates worldwide from the headquarters based in Paris, France and affiliate office in Cambridge, MA, USA. Nanobiotix has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. We develop first-in-class products with the aim to provide a maximum benefit with a minimum change in the medical practice in order to limit the hurdle of healthcare cost.
TypePublic
Founded2003
HQParis, FR
Websitenanobiotix.com

Latest Updates

Employees (est.) (Sept 2020)110
Share Price (Oct 2020)€6.6 (+2%)
Cybersecurity ratingDMore

Key People/Management at Nanobiotix

Laurent Levy

Laurent Levy

CEO
Alain Dostie

Alain Dostie

Chief Operating Officer
Brandon Owens

Brandon Owens

VP, Strategic Marketing and Corporate Communication
Philippe Mauberna

Philippe Mauberna

Chief Financial Officer
Patrick Tricoli

Patrick Tricoli

CEO, Board Member
Anne-Juliette Hermant

Anne-Juliette Hermant

Chief People Officer
Show more

Nanobiotix Office Locations

Nanobiotix has offices in Paris and Cambridge
Paris, FR (HQ)
60 rue de Wattignies
Cambridge, US
210 Broadway
Show all (2)

Nanobiotix Financials and Metrics

Nanobiotix Revenue

Market capitalization (19-Oct-2020)

170.4m

Closing stock price (19-Oct-2020)

6.6
Nanobiotix's current market capitalization is €170.4 m.
Show all financial metrics

Nanobiotix Cybersecurity Score

Cybersecurity ratingPremium dataset

D

67/100

SecurityScorecard logo

Nanobiotix Online and Social Media Presence

Embed Graph

Nanobiotix News and Updates

Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology

NANOBIOTIX ANNOUNCES PUBLICATION OF PHASE III SOFT TISSUE SARCOMA DATA FOR FIRST-IN-CLASS NBTXR3 IN THE LANCET ONCOLOGY  

Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval

NANOBIOTIX ANNOUNCES FIRST EVER RADIOENHANCER TO RECEIVE EUROPEAN MARKET APPROVAL

Nanobiotix 2018 Annual Results

Paris, France and Cambridge, Massachusetts, USA, March 15, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited1 consolidated results for the fiscal year ende…

Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank

Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank

Nanobiotix Plans to Conduct Registered Public Offering in the United States

Nanobiotix Plans to Conduct Registered Public Offering in the United States
Show more

Nanobiotix Frequently Asked Questions

  • When was Nanobiotix founded?

    Nanobiotix was founded in 2003.

  • Who are Nanobiotix key executives?

    Nanobiotix's key executives are Laurent Levy, Alain Dostie and Brandon Owens.

  • How many employees does Nanobiotix have?

    Nanobiotix has 110 employees.

  • Who are Nanobiotix competitors?

    Competitors of Nanobiotix include Ligandal, NanoViricides and Savara Pharmaceuticals.

  • Where is Nanobiotix headquarters?

    Nanobiotix headquarters is located at 60 rue de Wattignies, Paris.

  • Where are Nanobiotix offices?

    Nanobiotix has offices in Paris and Cambridge.

  • How many offices does Nanobiotix have?

    Nanobiotix has 2 offices.